The Current Ratio as of September 2024 (TTM) for LAVA Therapeutics N.V. (LVTX) is 6.39

According to LAVA Therapeutics N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 6.39. This represents a change of -0.27% compared to the average of 6.41 of the last 4 quarters.

LAVA Therapeutics N.V. (LVTX) Historical Current Ratio (quarterly & annually)

How has LVTX Current Ratio performed in the past?

The mean historical Current Ratio of LAVA Therapeutics N.V. over the last ten years is 10.34. The current 6.39 Current Ratio has changed 6.08% with respect to the historical average. Over the past ten years (40 quarters), LVTX's Current Ratio was at its highest in in the December 2021 quarter at 30.80. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

LAVA Therapeutics N.V. (LVTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of LAVA Therapeutics N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

LAVA Therapeutics N.V. (LVTX) Average Current Ratio

How has LVTX Current Ratio performed in the past?

The current Current Ratio of LAVA Therapeutics N.V. (LVTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

LAVA Therapeutics N.V. (LVTX) Current Ratio vs. Peers

How is LVTX’s Current Ratio compared to its peers?

LAVA Therapeutics N.V.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (5.32), less than PMV Pharmaceuticals, Inc. (19.22), greater than Miromatrix Medical Inc. (3.46), greater than ZIVO Bioscience, Inc. (0.17), greater than Bionomics Limited (3.81), less than Edgewise Therapeutics, Inc. (30.24), less than Ikena Oncology, Inc. (18.22), less than Design Therapeutics, Inc. (41.42), greater than Xilio Therapeutics, Inc. (2.02), less than Eliem Therapeutics, Inc. (60.41), less than Aerovate Therapeutics, Inc. (6.51), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (16.16), less than Rezolute, Inc. (11.82), less than AN2 Therapeutics, Inc. (10.61), less than Generation Bio Co. (7.42), less than Kronos Bio, Inc. (8.49), less than Erasca, Inc. (16.79), greater than C4 Therapeutics, Inc. (5.09), less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (15.06), less than Achilles Therapeutics plc (8.24), less than NextCure, Inc. (8.35), greater than Assembly Biosciences, Inc. (2.74),

Build a custom stock screener for LAVA Therapeutics N.V. (LVTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LAVA Therapeutics N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

LAVA Therapeutics N.V. (LVTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like LAVA Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.